GT200200279A - Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma - Google Patents
Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asmaInfo
- Publication number
- GT200200279A GT200200279A GT200200279A GT200200279A GT200200279A GT 200200279 A GT200200279 A GT 200200279A GT 200200279 A GT200200279 A GT 200200279A GT 200200279 A GT200200279 A GT 200200279A GT 200200279 A GT200200279 A GT 200200279A
- Authority
- GT
- Guatemala
- Prior art keywords
- asthma
- activity
- treatment
- cell factor
- precursor cell
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA PRESENTE INVENCION PROVEE DE ANTICUERPOS HUMANOS ESPECIFICOS PARA EL FACTOR DE LAS CELULAS PRECURSORAS QUE CONTIENEN POR LO MENOS UNA CDR DERIVADA DE UNA BIBLIOTECA COMBINATORIA DE ANTICUERPOS. LA INVENCION PROVEE, ADEMAS, DE COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN LOS ANTICUERPOS PARA TRATAR EL ASMA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34217401P | 2001-12-17 | 2001-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200200279A true GT200200279A (es) | 2003-07-18 |
Family
ID=23340685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200200279A GT200200279A (es) | 2001-12-17 | 2002-12-17 | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma |
Country Status (8)
Country | Link |
---|---|
US (2) | US7285640B2 (es) |
AR (1) | AR037756A1 (es) |
AU (1) | AU2002361720A1 (es) |
GT (1) | GT200200279A (es) |
HN (1) | HN2002000366A (es) |
TW (1) | TW200305435A (es) |
UY (1) | UY27583A1 (es) |
WO (1) | WO2003051311A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
WO2006002064A2 (en) * | 2004-06-14 | 2006-01-05 | Aerovance, Inc. | Antibody inhibiting stem cell factor activity and use for treatment of asthma |
TW200902555A (en) * | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
EP2465870A1 (en) * | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
EP2158315B1 (en) * | 2007-06-25 | 2016-03-23 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods of modifying antibodies, and modified antibodies with improved functional properties |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
WO2009135001A2 (en) * | 2008-04-30 | 2009-11-05 | University Of Pittsburgh- Commonwealth System Of Higher Education | Methods and compositions for regulating th2 and th17 responses |
WO2010036851A2 (en) * | 2008-09-26 | 2010-04-01 | Wyeth Llc | Single chain antibody library design |
US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
GB2559498B (en) * | 2011-01-10 | 2018-10-24 | Univ Michigan Regents | Stem cell factor inhibitor |
KR101384360B1 (ko) * | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
KR20230066647A (ko) | 2016-06-17 | 2023-05-16 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
KR20220079561A (ko) | 2019-09-16 | 2022-06-13 | 옵시디오, 엘엘씨 | 항-줄기세포 인자 항체 및 이의 사용 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US6187559B1 (en) * | 1997-08-28 | 2001-02-13 | Novartis Ag | Phospholipase D gene |
US6576812B1 (en) * | 1999-05-06 | 2003-06-10 | The Trustees Of Columbia University In The City Of New York | Compound screening assays using a transgenic mouse model of human skin diseases |
EP1285081A2 (en) * | 2000-05-30 | 2003-02-26 | ICH Productions Limited | Improved methods of transfection |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
-
2002
- 2002-12-09 AR ARP020104759A patent/AR037756A1/es unknown
- 2002-12-13 UY UY27583A patent/UY27583A1/es not_active Application Discontinuation
- 2002-12-16 AU AU2002361720A patent/AU2002361720A1/en not_active Abandoned
- 2002-12-16 HN HN2002000366A patent/HN2002000366A/es unknown
- 2002-12-16 US US10/320,231 patent/US7285640B2/en not_active Expired - Fee Related
- 2002-12-16 TW TW091136219A patent/TW200305435A/zh unknown
- 2002-12-16 WO PCT/US2002/040227 patent/WO2003051311A2/en not_active Application Discontinuation
- 2002-12-17 GT GT200200279A patent/GT200200279A/es unknown
-
2004
- 2004-06-14 US US10/867,506 patent/US20050112698A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7285640B2 (en) | 2007-10-23 |
UY27583A1 (es) | 2003-06-30 |
US20050112698A1 (en) | 2005-05-26 |
AR037756A1 (es) | 2004-12-01 |
WO2003051311A2 (en) | 2003-06-26 |
HN2002000366A (es) | 2003-04-21 |
WO2003051311A3 (en) | 2004-09-30 |
TW200305435A (en) | 2003-11-01 |
AU2002361720A8 (en) | 2003-06-30 |
US20030194405A1 (en) | 2003-10-16 |
AU2002361720A1 (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Virard et al. | Cold atmospheric plasma induces a predominantly necrotic cell death via the microenvironment | |
GT200200279A (es) | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma | |
NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
UY28342A1 (es) | Nuevos compuestos | |
ATE361084T1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
UY28348A1 (es) | Compuestos novedosos | |
CL2008001813A1 (es) | Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04). | |
BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
BR0308429A (pt) | Aroilpiridinonas monocìclicas como agentes antiinflamatórios | |
UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
CO5640037A2 (es) | Derivados de la quinazolina para el tratamiento del cancer | |
CR8778A (es) | Revestimientos de azucar y metodos para estos | |
CY1112721T1 (el) | Νεοι συνδετες που διαμορφωνουν τους υποδοχεις rαr, και χρηση αυτων στην ιατρικη για τον ανθρωπο και στα καλλυντικα | |
ES2194501T3 (es) | Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
EA200501586A1 (ru) | Фармацевтические продукты | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
ECSP078057A (es) | Formulaciones de estrógenos conjugados y bazedoxifeno | |
UY28366A1 (es) | Compuestos químicos | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
NO20043792L (no) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
BRPI0509667B8 (pt) | composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto | |
BRPI0518554A2 (pt) | uso de um inibidor de pde3 |